Results 121 to 130 of about 58,087 (312)

Prospects in folate receptor-targeted radionuclide therapy

open access: yesFrontiers in Oncology, 2013
Targeted radionuclide therapy is based on systemic application of particle-emitting radiopharmaceuticals which are directed towards a specific tumor-associated target. Accumulation of the radiopharmaceutical in targeted cancer cells results in high doses
Cristina eMüller   +2 more
doaj   +1 more source

Computational generation of tailored radionuclide libraries for alpha-particle and gamma-ray spectrometry [PDF]

open access: yes
Radionuclide identification is a radioanalytical method employed in various scientific disciplines that utilize alpha-particle or gamma-ray spectrometric assays, ranging from astrophysics to nuclear medicine. Radionuclide libraries in conventional radionuclide identification systems are crafted in a manual fashion, accompanying labor-intensive and ...
arxiv   +1 more source

Dilated cardiomyopathy evaluation with Imagenomics: combining multimodal cardiovascular imaging and genetics

open access: yesESC Heart Failure, EarlyView.
Systematic approach to dilated cardiomyopathy diagnosis. Dilated cardiomyopathy is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic disfunction unexplained by abnormal loading conditions or coronary artery disease.
Kristian Galanti   +14 more
wiley   +1 more source

Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: a 3D analysis of SPECT/CT images [PDF]

open access: yesarXiv, 2019
To meet the current need for skeletal tumor-load estimation in prostate cancer (mCRPC), we developed a novel approach, based on adaptive bone segmentation. In this study, we compared the program output with existing estimates and with the radiological outcome. Seventy-six whole-body 99mTc-DPD-SPECT/CT from mCRPC patients were analyzed.
arxiv  

Investigation of production routes for the 161Ho Auger-electron emitting radiolanthanide, a candidate for therapy

open access: yes, 2013
The radiolanthanide 161Ho (2.48 h) is a promising Auger-electron emitter for internal radiotherapy that can be produced with particle accelerators. The excitation functions of the natDy(p,xn)161Ho and natDy(d,x)161Ho reactions were measured up to 40 and ...
Ditrói, F.   +4 more
core   +1 more source

Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer

open access: yesExploration, EarlyView.
Considering the rapid progression of cancer in most cases, any delay in evaluating therapy outcomes poses a significant threat to patients’ lives. Consequently, it is imperative to implement stratification and conduct timely evaluations of therapeutic effects either before or during the early stages of cancer treatment.
Qinrui Fu
wiley   +1 more source

Development of a high-resolution and high efficiency Single Photon detector for studying cardiovascular diseases in mice [PDF]

open access: yesarXiv, 2019
SPECT systems using pinhole apertures permit radiolabeled molecular distributions to be imaged in vivo in small animals. Nevertheless studying cardiovascular diseases by means of small animal models is very challenging. Specifically, submillimeter spatial resolution, good energy resolution and high sensitivity are required. We designed what we consider
arxiv  

Comparison of technetium-99m IgG with technetium-99m red blood cells labeling in cardiac blood-pool scintigraphy: A preliminary study [PDF]

open access: yes, 2011
This first clinical prospective study was conducted to use of technetium-99m immunoglobulin G (99mTc-IgG) as compared with autologous 99mTc-red blood cells (RBC) in gated blood pool ventriculography.
Amini, A.   +7 more
core  

First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. [PDF]

open access: yes, 2018
PURPOSE: To investigate the utility of 153Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical failure with no clinical evidence of osseous metastases.
Girvigian, Michael R.   +10 more
core   +2 more sources

Home - About - Disclaimer - Privacy